NanoString Technologies Releases Operating Results for Third Quarter of 2019
SEATTLE--(BUSINESS WIRE)--Nov 4, 2019--
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter of 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104005837/en/
GeoMx DSP featured on the cover of the September issue of the journal Clinical Cancer Research. (Photo: Business Wire)
Third Quarter Financial Highlights
“During the third quarter we achieved the seventh consecutive quarter of double-digit revenue growth in our core nCounter® business, driven by strong instrument placements and an expanded consumable portfolio,” said Brad Gray, president and CEO of NanoString. “The shipment of our first commercial GeoMx DSP instruments during the third quarter accelerated our instrument revenue growth to more than 40%, and we see positive leading indicators of GeoMx interest including record demand for our GeoMx Technology Access Program.”
Recent Business Highlights
GeoMx Digital Spatial Profiling (DSP) Platform
Third Quarter Financial Results
Product and service revenue for the three months ended September 30, 2019 increased by 23% to $26.3 million, as compared to $21.5 million for the third quarter of 2018. Instrument revenue was $8.0 million, an increase of 48% compared to the prior year period. Consumables revenue, excluding Prosigna, was $12.7 million, an increase of 14% compared to the prior year period, with growth driven primarily by sales of our panel products. Prosigna IVD kit revenue remained flat at $2.5 million as compared to the prior year period. Service revenue was $3.1 million, an increase of 31% compared to the prior year period, reflecting continued growth in demand for our GeoMx DSP Technology Access Program and an increased number of service contracts associated with our growing installed base of nCounter instruments. Gross margin on product and service revenue was 59% compared to 57% in the prior year period, reflecting a mix shift towards our MAX and FLEX nCounter instruments as well as sales of our new GeoMx DSP instruments.
Collaboration revenue totaled $4.3 million, compared to $7.2 million for the prior year period, and was derived primarily from our collaboration with Lam Research. Cash received from collaborators totaled $4.5 million during the quarter, primarily reflecting activity relating to our collaboration with Lam Research and the remaining activities for our Celgene collaboration, which ended during the second quarter of this fiscal year.
Research and development expense increased by 2% to $17.0 million compared to $16.7 million for the prior year period, primarily due to higher stock-based compensation expense. Selling, general and administrative expense increased by 31% to $23.4 million compared to $17.8 million for the prior year period, primarily reflecting increased investment in personnel and commercial launch activities related to GeoMx DSP and higher stock-based compensation expense.
Net loss was $22.7 million, or a loss of $0.64 per share, compared with $16.5 million, or $0.56 per share, for the prior year period.
Outlook for 2019
The company updated its revenue and gross margin guidance for fiscal 2019, with results expected as follows:
The company also updated its guidance for certain operating expenses and other items. These updates reflect additional investments directed to capture demand for and support the launch of GeoMx DSP, as well as higher expected stock-based compensation expense. For the full year 2019, the company now expects:
Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Individuals interested in listening to the conference call may do so by dialing (866) 211-0364 for domestic callers, or (647) 689-6861 for international callers. Please reference Conference ID 9358402. To listen to a live webcast, please visit the investor relations section of the company’s website at www.nanostring.com. A replay of the call will be available beginning November 4, 2019 at 7:30 pm ET through midnight ET on November 11, 2019. To access the replay, dial (800) 585-8367 or (416) 621-4642 and reference Conference ID: 9358402. The webcast will also be available on the company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 2,800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The company’s technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for future revenue growth, the impact of new products and expansion into new markets, the company’s anticipated uses or sources of cash, the growth trajectory of the company’s nCounter and GeoMx DSP systems, the anticipated demand for new platforms, the anticipated benefits of the company’s collaboration relationships, the timing of development funding and the company’s estimated 2019 operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString logo, NanoString, NanoString Technologies, GeoMx, Hyb & Seq, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions. All other trademarks are the property of their respective owners. All rights reserved.
NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended
Nine Months Ended
In vitro diagnostic kits
Total product and service revenue
Costs and expenses:
Cost of product and service revenue
Research and development
Selling, general and administrative
Total costs and expenses (a) (b)
Loss from operations
Other income (expense):
Other expense, net
Total other expense, net
Net loss before provision for income taxes
Provision for income taxes
Net loss per share, basic and diluted
Shares used in calculating basic and diluted net loss per share
(a) Includes $4.7 million and $2.8 million of stock-based compensation expense for the three months ended September 30, 2019 and 2018, respectively, and $12.7 million and $8.7 million for the nine months ended September 30, 2019 and 2018, respectively.
(b) Includes $1.2 million and $1.0 million of depreciation and amortization expense for the three months ended September 30, 2019 and 2018, respectively, and $3.6 million and $3.0 million for the nine months ended September 30, 2019 and 2018, respectively.
NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
Cash and cash equivalents
Accounts receivable, net
Prepaid expenses and other
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Liabilities and Stockholders’ Equity
Accrued compensation and other employee benefits
Deferred revenue, current portion
Deferred rent, current portion
Operating lease liabilities, current portion
Total current liabilities
Deferred revenue, net of current portion
Deferred rent and other long-term liabilities, net of current portion
Long-term debt, net of discounts
Operating lease liabilities, net of current portion
Total stockholders’ equity
Total liabilities and stockholders’ equity
View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005837/en/
CONTACT: Doug Farrell
Vice President, Investor Relations & Corporate Communications
KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS RESEARCH SCIENCE BIOTECHNOLOGY
SOURCE: NanoString Technologies, Inc.
Copyright Business Wire 2019.
PUB: 11/04/2019 04:01 PM/DISC: 11/04/2019 04:01 PM